SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sustained rally to a 52-week high and push through a long-watched round-number level are driving attention, with holders celebrating the recovery while skeptics question whether it can hold without a stronger company-specific catalyst. Traders are also watching the upcoming earnings report and pipeline developments for confirmation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are focused on reports that Trump ruled out an immediate U.S. strike on Iran, with many interpreting the news as a possible relief-driven futures bounce while others argue conflict and oil-supply risks are merely delayed. The debate is amplifying an already cautious, volatile outlook ahead of the Fed decision, major tech earnings and inflation data.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus stock-and-warrant offering has intensified concern about shareholder dilution and contributed to a steep selloff, alongside broader weakness in nuclear stocks. Traders are divided between viewing the pullback as a buying opportunity tied to domestic uranium-enrichment demand and worrying that valuation, expansion costs, and execution risks outweigh the long-term HALEU and DOE-contract potential.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

FDA clearance to expand Alpha Taus recurrent glioblastoma REGAIN trial and anticipated follow-up data are driving attention, alongside progress in its pancreatic cancer program. Traders are optimistic about the early GBM signal but acknowledge that it comes from a small cohort and await larger-data validation.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

Discussion is focused on the $17.05 million investor settlement: eligible shareholders are being reminded to file claims before the deadline, with a final approval hearing scheduled immediately afterward. Some traders view clearing the legal overhang as a positive, while others emphasize the settlements limited per-share recovery and historical allegations about Twists production and financial disclosures.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is under pressure as gold has weakened and rising rate expectations and yields weigh on precious metals and miners. Traders are divided between viewing the pullback and nearby support as a buying opportunity and expecting further losses if support gives way.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Volatile natural-gas futures are driving discussion, with traders weighing winter-weather demand and storage reports against mild-weather forecasts, strong production, and ample supply; pipeline and Freeport disruptions have also sparked sharp moves. Views are split on whether gas can sustain a rebound, while many warn that BOILs leveraged futures exposure and decay make it especially risky to hold.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating Iran and broader Middle East tensions could disrupt oil supplies and shipping. Bulls see tight supply and continued geopolitical risk supporting the move, while bears argue the rally may be overextended and could reverse if tensions ease or a deal emerges.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Traders are focused on SQQQ as a leveraged hedge against the Nasdaq, citing tech weakness and concerns that heavy AI spending may not deliver adequate returns, alongside interest-rate and geopolitical risks. Some expect further downside in tech and favor SQQQ, while others caution that its daily leverage can erode value and that a Nasdaq rebound could reverse its gains.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung-cancer results for IMDELLTRA plus Imfinzi are drawing attention, with traders focused on the reported survival benefit and potential to expand the drugs role in earlier treatment. The community views the data as a meaningful pipeline catalyst, though some question how much it will change Amgens broader growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Relief Coming For BULL Stock? CEO Says Next Month's PDT Rule Reversal Could Unlock 20% More Trading

Equity

WeBull reported Q1 results on Thursday, clocking a 90% growth in customer assets.

GraniteShares ETF Trust - GraniteShares 2x Long BULL Daily ETF

Bullish Sentiment

<ul class="summary-bullets"><li>CEO Anthony Denier expects the reversal of the Pattern Day Trader rule to drive a significant increase in transaction activity over time.&nbsp;</li><li>Denier also said that AI was central to Webull’s long-term strategy.</li><li>The stockbroker posted a 36% growth in Q1 revenue of $159.93 million, beating Wall Street expectations.</li></ul>Shares of Webull Corp. (BULL) rose more than 1.3% in overnight trading headed into Friday, on track to reverse three consecutive days in the red, after the company’s deposits grew significantly and a reversal of the Pattern Day Trader (PDT) rule boosted sentiment.For the quarter, the company’s customer assets grew 90% year-on-year to $24 billion, while institutional business also posted significant growth.CEO Anthony Denier said that the results signaled not just a strong quarter but also “confirm that Webull is executing on the right long-term strategy.”Retail interest in the company surged, with message volumes on the platform growing more than 634% in the last 24 hours, even as sentiment jumped from ‘bearish’ to ‘extremely bullish’ in the same time.<h2 class="st-heading-2">BULL Q1 Snapshot</h2>The financial services company posted <a href="https://stocktwits.com/news-articles/markets/equity/bull-stock-jumps-amid-strong-user-deposit-growth-finra-approval/cZXCSoLRe8N">first-quarter</a> (Q1) revenue of $159.93 million, representing 36% YoY growth and ahead of Wall Street expectations, according to Fiscal.ai data. While WeBull posted a net loss of $0.04 per share, it narrowed YoY.<h2 class="st-heading-2">PDT Rule Reversal Boosts BULL Prospects</h2>Last month, the Financial Industry Regulatory Authority (FINRA) eliminated the Pattern Day Trader (PDT) rule, which required margin traders making four or more day trades in five business days to maintain at least $25,000 in their accounts. This is likely to boost the company's transaction volume.“The average account size at Webull as of our end-of-quarter AUM sits just below $5,000 per account. The biggest cohort of clients that we have on the Webull platform is directly impacted by this rule change,” Denier said.The CEO expects this to drive at least a 20% increase in transaction activity over time. “This is not going to happen on day one on June fourth, but I believe this will happen over time,” he said in a call with investors. “This is a very big event for us, and we’re making sure that we’re taking full advantage of it,” he added.<h2 class="st-heading-2">BULL’s AI Strategy</h2>Denier also noted that Webull is prioritizing long-term strategy over short-term margins, with AI central to its plans. The company’s 2026 roadmap focuses on improving tools for active traders, expanding globally, and strengthening its institutional and B2B infrastructure.The CEO highlighted the company’s new AI products, including Vega Analyst, Portfolio Blueprint for one-click portfolio construction, and AI Portfolio for agentic trading and portfolio management.“AI sits at the center of everything we are building,” Denier reiterated.<h2 class="st-heading-2">BULL Stock: Retail Stance</h2>One user expressed optimism, saying the stock should be at least $25. The stock closed at $6.61 on Thursday.<stembedurl>https://stocktwits.com/Aj2121/message/654123215</stembedurl>Another user said, “We need new price target and coverage by the analysts.”<stembedurl>https://stocktwits.com/luckytrader20/message/654122851</stembedurl>However, another user sounded caution, saying, “broke major support today. This might drop in the coming weeks.”<stembedurl>https://stocktwits.com/St0ckmaster11/message/654127865</stembedurl><a href="https://stocktwits.com/symbol/BULL">BULL shares</a> have declined more than 47% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

 In this photo illustration, the Webull Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

BULL Stock Eyes Revival As CEO Bets PDT Rule Reversal Will Spark Trading Surge

Amplify Blockchain Technology ETF

Leverage Shares 2X Long BULL Daily ETF

Webull Corp

GraniteShares 2x Long BULL Daily ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

BULX GraniteShares 2x Long BULL Daily ETF

Fundamentals

Latest BULX News